10-Q: STERIS Q2 2026: Strong Revenue Growth, Profitability Up

STERIS plc reports robust Q2 and H1 fiscal 2026 results with significant revenue and operating income growth across all segments, driven by volume and pricing.

Summary

• Total revenues increased 9.9% to $1,460.3 million for the three months ended September 30, 2025, and 9.3% to $2,851.4 million for the six months ended September 30, 2025, compared to the prior year periods.
• Gross profit percentage improved to 44.2% for Q2 FY26 (from 43.6% in Q2 FY25) and 44.7% for H1 FY26 (from 44.1% in H1 FY25), driven by favorable pricing, productivity, and mix.
• Income from operations rose to $265.8 million for Q2 FY26 (from $219.7 million in Q2 FY25) and $511.8 million for H1 FY26 (from $405.2 million in H1 FY25).
• Net income attributable to shareholders was $191.9 million for Q2 FY26 and $369.2 million for H1 FY26.
• Diluted EPS from continuing operations was $1.94 for Q2 FY26 and $3.74 for H1 FY26.
• Cash flows from operations increased to $707.8 million for H1 FY26 from $554.5 million in H1 FY25.
• Free cash flow grew to $527.7 million for H1 FY26 from $344.5 million in H1 FY25.
• Debt-to-total capital ratio improved to 21.3% at September 30, 2025, from 23.6% at March 31, 2025.
• A targeted restructuring plan, adopted in May 2024, eliminated approximately 300 positions and is expected to improve income from operations by approximately $25.0 million per year in fiscal 2026 and beyond.
• The company completed a tuck-in acquisition in the Healthcare segment for approximately $15.0 million during H1 FY26.
• The Dental segment was divested on May 31, 2024, for $787.5 million cash consideration, plus potential contingent payment of up to $12.5 million, and is reported as discontinued operations.
• The Controlled Environment Certification Services (CECS) business was sold on April 1, 2024, for $41.9 million, recognizing a pre-tax gain of $19.2 million.
• The U.S. enacted the "One Big Beautiful Bill Act" (OBBBA) on July 4, 2025, which is not expected to have a material impact on the company's effective tax rate for the current period or fiscal 2026.
• The company is contesting IRS assertions regarding deemed dividend inclusions and associated withholding tax for fiscal and calendar year 2018, totaling approximately $50.0 million.

Sentiment

Score: 8

Explanation: The company demonstrated robust financial performance with significant revenue and operating income growth, improved gross margins, and strong cash flow generation. Strategic divestitures and restructuring efforts are yielding positive results, and the balance sheet has strengthened. While there are ongoing tax disputes and litigation, the overall financial health and operational efficiency appear strong.

Positives

• Strong revenue growth across all segments (Healthcare, AST, Life Sciences) for both three and six-month periods, driven by higher volume and pricing.
• Improved gross profit percentages due to favorable pricing (120 basis points for H1 FY26), productivity (80 basis points for H1 FY26), mix (10 basis points for H1 FY26), and other cost reductions (50 basis points for H1 FY26).
• Significant increase in income from operations for both periods, with Q2 FY26 up to $265.8 million from $219.7 million in Q2 FY25, and H1 FY26 up to $511.8 million from $405.2 million in H1 FY25.
• Substantial growth in cash flows from operations to $707.8 million for H1 FY26 (from $554.5 million in H1 FY25) and free cash flow to $527.7 million for H1 FY26 (from $344.5 million in H1 FY25), indicating strong liquidity and operational efficiency.
• Improved debt-to-total capital ratio to 21.3% at September 30, 2025, from 23.6% at March 31, 2025, reflecting a stronger financial position.
• Restructuring plan expected to enhance profitability and efficiency, with an anticipated $25.0 million annual improvement in income from operations from fiscal 2026 onwards.
• Successful divestiture of the Dental segment, generating $787.5 million cash proceeds used to pay down debt.
• Tuck-in acquisitions expanding product and service offerings in the Healthcare segment for approximately $15.0 million.
• Increased cash dividends declared per ordinary share ($1.20 for H1 FY26 vs. $1.09 for H1 FY25).

Negatives

• Gross profit percentage improvements were partially offset by unfavorable impacts from inflation (90 basis points for H1 FY26), tariff costs (80 basis points for H1 FY26), material costs (30 basis points for H1 FY26), and currency movements (10 basis points for Q2 FY26).
• Selling, general, and administrative expenses increased 5.8% for the six months ended September 30, 2025, primarily due to higher compensation and benefit costs, unfavorable foreign currency movements, and increased bad debt expense.
• Effective income tax rates increased in fiscal 2026 (23.6% for H1 FY26) compared to fiscal 2025 (21.3% for H1 FY25), primarily due to changes in geographic mix of projected profits and unfavorable changes in discrete items.
• Contesting IRS adjustments for fiscal and calendar year 2018, which could result in a cumulative tax liability of approximately $50.0 million if unsuccessful.

Risks

• Operating costs, pressure on pricing (including from inflation), customer loss, and business disruption could be greater than expected, leading to profit margin erosion.
• Inability to successfully integrate acquired businesses, including unknown liabilities or higher integration costs.
• Changes in tax laws or interpretations (including OBBBA), or adoption of tax treaties, could increase consolidated tax liabilities or result in STERIS being treated as a domestic corporation for U.S. federal tax purposes.
• Compliance with laws, court rulings, regulations, or other regulatory actions, or the outcome of pending or threatened litigation (e.g., ethylene oxide litigation), may delay new product/service introductions, impact production/supply/marketing, result in uncovered costs, or otherwise affect performance.
• Potential for international unrest, military conflicts, economic downturns, and effects of currency fluctuations.
• Delays in order receipt, order cancellations, or issues with manufacturing/shipment of products.
• Anticipated growth, performance, or other results may not be achieved, or timing/execution issues may adversely impact performance.
• Impacts of legislation, regulations, or orders by the U.S. administration/Congress, or responses by non-U.S. governments.
• Anticipated financial results, productivity improvements, cost savings, and growth synergies from acquisitions, restructuring efforts, and divestitures may not be realized or may be less than anticipated.
• Level of indebtedness could limit financial flexibility or increase future borrowing costs.
• Effects of changes in credit availability and pricing, and the ability of STERIS, customers, and suppliers to access credit markets.
• Increasing competition within the industry may pressure pricing or decrease demand.
• Labor-related issues such as strikes, unsuccessful union negotiations, and other workforce disruptions.
• Economic downturns and recessions could negatively impact business by reducing consumer and customer spending.
• An unfavorable outcome in the IRS tax dispute could be material to consolidated results of operations and cash flows for any one period.
• Uncertainty regarding the ultimate outcome or effect of current or future litigation, investigations, claims, or other proceedings, including the Illinois EO litigation.

Future Outlook

The company expects the targeted restructuring plan to enhance profitability and improve efficiency, leading to an approximate $25.0 million annual improvement in income from operations in fiscal 2026 and beyond. The recently enacted U.S. "One Big Beautiful Bill Act" (OBBBA) is not expected to have a material impact on the effective tax rate for fiscal 2026. The claims administration process for the Illinois EO litigation settlement is expected to continue through the first half of fiscal 2027.

Management Comments

• "WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe."
• The increase in revenues reflects the benefits of higher volume and pricing, with all three segments contributing to growth.
• The increase in gross profit percentage reflects favorable impacts from pricing, productivity, mix, and other cost reductions that were partially offset by unfavorable impacts from inflation and tariff costs.
• The increase in income from operations is primarily due to increased volume and pricing, partially offset by inflation and tariff costs, and the benefit of lower restructuring expenses in the first six months of fiscal 2026.
• The fiscal 2026 increase in cash flows from operations and free cash flow resulted from an increase in earnings and from the increase in cash provided by working capital improvements, also impacted by a decrease in capital expenditures.

Industry Context

The company's growth is largely driven by the aging global population, increasing demand for medical procedures (including preventive screenings), and customers' desire for greater operational efficiency within the healthcare, medical device, and pharmaceutical industries. The divestiture of the Dental segment allows for a sharper focus on core infection prevention and life science offerings, aligning with the broader trend of specialization in the healthcare sector.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Company is involved in legal proceedings, government investigations, and claims, including personal injury, product liability, product exposure (e.g., chemicals, gases, asbestos, radiation), property damage, commercial claims, financial, and employment matters.
• A subsidiary has been sued in Illinois state court by plaintiffs alleging cancer from ethylene oxide (EO) emissions from a facility (January 2005 to September 2008).
• On March 3, 2025, the company entered into binding confidential term sheets and settlement agreements to pay up to $48.2 million to settle substantially all pending EO-related personal injury claims in Cook County, Illinois.
• The company is contesting IRS assertions regarding deemed dividend inclusions and associated withholding tax for fiscal and calendar year 2018, which could result in a cumulative tax liability of approximately $50.0 million. Petitions have been filed with the U.S. Tax Court, and no reserves have been established.

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Positive impact from increased net income, EPS, cash dividends, and share repurchase program. Improved debt-to-total capital ratio strengthens financial stability.
• Employees: Approximately 300 positions eliminated as part of the restructuring plan, impacting those employees. Michael J. Tokich's transition to an advisory role.
• Customers: Continued expansion of product and service offerings through tuck-in acquisitions. Focus on infection prevention and life science products and services.
• Creditors: Debt repayments and improved debt-to-total capital ratio indicate a stronger financial position, reducing credit risk.
• Regulatory Authorities: Ongoing engagement with the IRS regarding tax disputes and compliance with new tax legislation (OBBBA). Addressing legal proceedings related to environmental claims (Illinois EO litigation).

Next Steps

• Continue to implement the targeted restructuring plan, which is expected to improve income from operations by approximately $25.0 million per year in fiscal 2026 and beyond.
• Continue to contest IRS assertions regarding deemed dividend inclusions and associated withholding tax for fiscal and calendar year 2018.
• Proceed with the claims administration process for the Illinois EO litigation settlement, expected to continue through the first half of fiscal 2027.
• Assess the impact of new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-05, ASU 2025-06) on future disclosures and financial statements.
• Michael J. Tokich will serve as Senior Financial Advisor on an as-needed basis from January 1, 2026, through March 31, 2026, with a possible extension for up to an additional six months.

Key Dates

Recommendation

STERIS plc has demonstrated exceptional financial performance in the first half of fiscal 2026, with robust revenue growth, improved profitability, and strong cash flow generation across all key segments. The strategic divestiture of the Dental segment and ongoing restructuring efforts are clearly contributing to enhanced efficiency and a stronger balance sheet, as evidenced by the improved debt-to-total capital ratio. While the company faces ongoing legal and tax challenges, these appear to be managed, and the core business momentum driven by favorable market trends (aging population, demand for medical procedures) is compelling. The consistent increase in cash dividends and active share repurchase program further underscore management's confidence and commitment to shareholder returns. This filing presents a very positive outlook for continued growth and profitability, making it an attractive investment.

Keywords

Healthcare, Infection Prevention, Sterilization, Life Sciences, Medical Devices, Pharmaceuticals, Financial Results, Revenue Growth, Operating Income, Cash Flow, Restructuring, Acquisitions, Divestitures, SEC Filing, 10-Q